# US 10,870,694 B2 · Composition and methods of treating B cell disorders > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 10,870,694 B2 - Document ID: US10870694B2 - Status: Granted - Kind: B2 - Application number: 16/330,188 - Filed: 2017-09-05 - Published: 2019-09-12 - Granted: 2020-12-22 - Earliest claimed: 2016-09-02 - Assignees: Dana-Farber Cancer Institute, Inc. - Applicants: Dana-Farber Cancer Institute, Inc. - Inventors: Wayne A. Marasco - Web page: https://patentgrep.com/patent/US10870694B2 ## CPC - C07K 16/18: against material from animals or humans - A61K 39/39566: {against immunoglobulins, e.g. anti-idiotypic antibodies} - A61P 35/02: specific for leukemia - C07K 16/2803: {against the immunoglobulin superfamily} - C07K 16/4241: {against anti-human or anti-animal Ig} - A61K 2039/505: {comprising antibodies} - A61K 2039/545: {characterised by the dose, timing or administration schedule} - C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered - C07K 2317/35: Valency - C07K 2317/565: Complementarity determining region [CDR] - C07K 2317/622: Single chain antibody (scFv) - C07K 2317/732: Antibody-dependent cellular cytotoxicity [ADCC] - C07K 2317/734: Complement-dependent cytotoxicity [CDC] - C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding - C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value - C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS ## Abstract The present invention comprises methods of using a humanized monoclonal antibody that binds to the human immunoglobulin heavy chain variable region germline gene VH1-69 to treat B-cell disorders. ## Claims ### Claim 1 A method of selectively killing a B-cell expressing a IGHV1-69 BCR comprising contacting the B-cell with a chimeric antigen receptor comprising an huG6 antibody. ### Claim 2 (depends on 1) The method of claim 1, wherein said antibody is monovalent or bivalent. ### Claim 3 (depends on 1) The method of claim 1, wherein said antibody is a single chain antibody. ### Claim 4 (depends on 1) The method of claim 1, wherein the huG6 antibody comprises: a humanized heavy chain with three CDRs comprising an amino acid sequence GYTFTSYW (SEQ ID NO: 1); VSPGNSDT (SEQ ID NO: 2); and TRSRYGNNALDY (SEQ ID NO: 3); and a humanized light chain with three CDRs that include an amino acid sequence selected from the group consisting of the amino acid sequences of QGISSNIVW (SEQ ID NO: 4); HGT (SEQ ID NO: 5); and VQYSQFPPT (SEQ ID NO: 6). ### Claim 5 (depends on 1) The method of claim 1, wherein the huG6 antibody comprises: a. a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 14 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:8; b. a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 10 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 12; or c. a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 14 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:12. ### Claim 6 (depends on 1) The method of claim 1, wherein the chimeric antigen receptor is contacted with the B-cell prior to, concurrently with, or subsequent to contacting the B-cell with a chemotherapeutic agent. ### Claim 7 A method of selectively killing a B-cell expressing a IGHV1-69 BCR comprising administering to a subject in need thereof a chimeric antigen receptor comprising an huG6 antibody. ### Claim 8 (depends on 7) The method of claim 7, wherein the subject has a cancer, an autoimmune disorder or an inflammatory disorder. ### Claim 9 (depends on 7) The method of claim 7, wherein the subject has chronic lymphocytic leukemia of B-cell phenotype (B-CLL), thrombotic thrombocytopenic purpura (TPP), idiopathic thrombocytopenia purpura (ITP) or cryoglobulinemia. ### Claim 10 (depends on 7) The method of claim 7, wherein said chimeric antigen receptor is administered prior to, concurrently with, or subsequent to the administration of a chemotherapeutic agent. ### Claim 11 A method of selectively killing a B-cell expressing a IGHV1-69 BCR comprising contacting the B-cell with a chimeric antigen receptor comprising an huG6 antibody, wherein said chimeric antigen receptor comprising an huG6 antibody is contacted with the B-cell prior to, concurrently with, or subsequent to contacting the B-cell with a chemotherapeutic agent. ### Claim 12 A method of selectively killing a B-cell expressing a IGHV1-69 BCR comprising administering to a subject in need thereof a chimeric antigen receptor comprising an huG6 antibody, wherein said chimeric antigen receptor comprising an huG6 antibody is administered to, concurrently with, or subsequent to the administration of a chemotherapeutic agent.